Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    Hamdan Bin Rashid Al Maktoum Foundation for Medical and Educational Sciences organized the “Pioneers of Excellence Forum” initiative, with the participation of 23 educational excellence award winners and educational coordinators… The post Hamdan Bin Rashid Al Maktoum Foundation Organizes “Pioneers of Excellence Forum” for Gulf Award Winners and Educational Coordinators appeared first on Web-Release.